Moss Genomics（MOSS）株式概要モス・ジェノミクス社は、カナダで個別化された健康、アンチエイジング、ウェルネス製品を製造・販売している。 詳細MOSS ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析財務データは報告されていない 意味のある時価総額がありません ( CA$2M )株式の流動性は非常に低い すべてのリスクチェックを見るMOSS Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueCA$Current PriceCA$0.03該当なし内在価値ディスカウントEst. Revenue$PastFuture012016201920222025202620282031Revenue CA$1.0Earnings CA$0.2AdvancedSet Fair ValueView all narrativesMoss Genomics Inc. 競合他社Psyence GroupSymbol: CNSX:PSYGMarket cap: CA$1.9mCytophage TechnologiesSymbol: TSXV:CYTOMarket cap: CA$2.0mNeural TherapeuticsSymbol: CNSX:NURLMarket cap: CA$2.5mEntheon BiomedicalSymbol: CNSX:ENBIMarket cap: CA$1.4m価格と性能株価の高値、安値、推移の概要Moss Genomics過去の株価現在の株価CA$0.0352週高値CA$0.2052週安値CA$0.005ベータ01ヶ月の変化-14.29%3ヶ月変化-14.29%1年変化-79.31%3年間の変化-84.62%5年間の変化n/aIPOからの変化-85.19%最新ニュースお知らせ • Nov 13Moss Genomics Inc. announced that it has received CAD 0.1 million in fundingMoss Genomics Inc. announces that it has closed a non-brokered private placement of 555,555 common shares at CAD 0.18 per share for gross proceeds of CAD 100,000 on November 12, 2025. No finder’s fees were paid.お知らせ • Aug 27Moss Genomics Inc., Annual General Meeting, Sep 29, 2025Moss Genomics Inc., Annual General Meeting, Sep 29, 2025.New Risk • May 17New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 29% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (74% average weekly change). Market cap is less than US$10m (CA$4.62m market cap, or US$3.30m). Minor Risk Shareholders have been diluted in the past year (29% increase in shares outstanding).お知らせ • Feb 27+ 1 more updateMoss Genomics Inc. Appoints Michal Goldstein as its Fractional Chief Financial OfficerMoss Genomics Inc. announced the appointment of Michal "Mickey" Goldstein as its new fractional Chief Financial Officer (CFO). Moss Genomics is confident that Ms. Goldstein's extensive financial expertise and leadership experience will be instrumental in supporting the Company's continued expansion and operational efficiency.お知らせ • Feb 04Moss Genomics Inc. announced that it expects to receive CAD 0.36 million in fundingMoss Genomics Inc. announced a non-brokered private placement on February 3, 2025. The company will issue 2,000,000 common shares at price of CAD 0.18 per share for aggregate proceeds of up to CAD 360,000. The Offering may close in one or more tranches and is subject to the approval of the Canadian Securities Exchange. All securities issued under the Offering will be subject to a statutory hold period expiring four months plus one day from the date of issuance.お知らせ • Dec 25Moss Genomics Inc. announced that it expects to receive CAD 0.25 million in fundingMoss Genomics Inc. announced a non-brokered private placement that it will issue up to 2,500,000 common shares of the company at an issue price of CAD 0.10 per share for the gross proceeds of up to CAD 250,000 on December 24, 2024. The Offering may close in one or more tranches and is subject to the approval of the Canadian Securities Exchange. All securities issued under the Offering will be subject to a statutory hold period expiring four months plus one day from the date of issuance. Additionally, the Company may pay finders' fees in connection with the Offering in accordance with the policies of the Exchange. The Company also announces that it has granted a total of 600,000 stock options to certain directors, officers and consultants of the Company. The options are each exercisable to purchase one common share of the Company at an exercise price of CAD 0.10 for a period of 5 years.最新情報をもっと見るRecent updatesお知らせ • Nov 13Moss Genomics Inc. announced that it has received CAD 0.1 million in fundingMoss Genomics Inc. announces that it has closed a non-brokered private placement of 555,555 common shares at CAD 0.18 per share for gross proceeds of CAD 100,000 on November 12, 2025. No finder’s fees were paid.お知らせ • Aug 27Moss Genomics Inc., Annual General Meeting, Sep 29, 2025Moss Genomics Inc., Annual General Meeting, Sep 29, 2025.New Risk • May 17New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 29% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (74% average weekly change). Market cap is less than US$10m (CA$4.62m market cap, or US$3.30m). Minor Risk Shareholders have been diluted in the past year (29% increase in shares outstanding).お知らせ • Feb 27+ 1 more updateMoss Genomics Inc. Appoints Michal Goldstein as its Fractional Chief Financial OfficerMoss Genomics Inc. announced the appointment of Michal "Mickey" Goldstein as its new fractional Chief Financial Officer (CFO). Moss Genomics is confident that Ms. Goldstein's extensive financial expertise and leadership experience will be instrumental in supporting the Company's continued expansion and operational efficiency.お知らせ • Feb 04Moss Genomics Inc. announced that it expects to receive CAD 0.36 million in fundingMoss Genomics Inc. announced a non-brokered private placement on February 3, 2025. The company will issue 2,000,000 common shares at price of CAD 0.18 per share for aggregate proceeds of up to CAD 360,000. The Offering may close in one or more tranches and is subject to the approval of the Canadian Securities Exchange. All securities issued under the Offering will be subject to a statutory hold period expiring four months plus one day from the date of issuance.お知らせ • Dec 25Moss Genomics Inc. announced that it expects to receive CAD 0.25 million in fundingMoss Genomics Inc. announced a non-brokered private placement that it will issue up to 2,500,000 common shares of the company at an issue price of CAD 0.10 per share for the gross proceeds of up to CAD 250,000 on December 24, 2024. The Offering may close in one or more tranches and is subject to the approval of the Canadian Securities Exchange. All securities issued under the Offering will be subject to a statutory hold period expiring four months plus one day from the date of issuance. Additionally, the Company may pay finders' fees in connection with the Offering in accordance with the policies of the Exchange. The Company also announces that it has granted a total of 600,000 stock options to certain directors, officers and consultants of the Company. The options are each exercisable to purchase one common share of the Company at an exercise price of CAD 0.10 for a period of 5 years.お知らせ • May 31Moss Genomics Inc., Annual General Meeting, Jul 25, 2024Moss Genomics Inc., Annual General Meeting, Jul 25, 2024.Board Change • May 09Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Apr 17Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Mar 18Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Nov 30Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Nov 13Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Oct 25Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Sep 21Moss Genomics Inc. Expects to Launch Its 90-Second Urine Test and Smartphone App in December 2023Moss Genomics Inc. announced that it expects to launch its 90-second urine test and accompanying smartphone app in December 2023. This revolutionary product is set to transform the way individuals monitor their health and detect potential medical conditions, offering quick, accurate, and convenient results at their fingertips. Moss 90-second urine test utilizes cutting-edge technology to provide rapid and accurate results. By simply collecting a small urine sample, users will receive comprehensive health insights within just 90 seconds. This breakthrough technology eliminates the need for time-consuming laboratory tests. Accompanying the urine test will be a user-friendly smartphone app, providing users with a comprehensive analysis of their health data. Through the app, users will be able to track their health trends, set personalized health goals, and receive real-time notifications and recommendations based on their test results. The app will also offer a secure platform for users to share their data with healthcare professionals, enabling remote monitoring and personalized medical advice. The Moss team, alongside its partners, have worked to ensure the accuracy and reliability of the urine test and app. Extensive testing has been conducted to validate the technology's effectiveness. The results have been overwhelmingly positive, demonstrating the test's ability to detect a wide range of health conditions with high accuracy. The launch of the 90-second urine test and smartphone app is scheduled for December 2023.Board Change • Jul 24Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jun 17Moss Genomics Inc. Introduces Diet and Vitamin ReportsMoss Genomics Inc. announced the introduction of its diet and vitamin reports which can be ordered directly to your home via its online platform. Up to 80 million genetic variants are analyzed to provide the most insightful information concerning dietary needs and vitamin deficiencies. its diet reports provide information about celiac, alcohol sensitivity, sweet tooth, caffeine related anxiety, hunger, food allergies, response to carbohydrates, bitter taste sensitivity and lactose intolerance. its Reports highlight micronutrient deficiencies and requirements such as Riboflavin, MTHFR (folate), Vitamin B12, Vitamin C, Vitamin D and Iron. These Reports give customers the opportunity to further explore and understand their genetic data. Moss customers can enjoy a comprehensive suite of genetic reports available in its online shop. Moss has created an online healthcare and technology platform integrating labs, services, and products in a shared economy. Moss provides comprehensive and affordable, at-home genetic and microbiome testing paired with personalized wellness reports and offerings to promote total gut, mind, and body health. The Company's services include health reports, personalized food and nutrition recommendations, and a social media platform that allows customers to form communities based on their specific health needs.Board Change • Jun 01Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Mar 02Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Feb 01Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.株主還元MOSSCA BiotechsCA 市場7D0%6.7%1.5%1Y-79.3%19.8%33.7%株主還元を見る業界別リターン: MOSS過去 1 年間で19.8 % の収益を上げたCanadian Biotechs業界を下回りました。リターン対市場: MOSSは、過去 1 年間で33.7 % のリターンを上げたCanadian市場を下回りました。価格変動Is MOSS's price volatile compared to industry and market?MOSS volatilityMOSS Average Weekly Movementn/aBiotechs Industry Average Movement11.2%Market Average Movement10.2%10% most volatile stocks in CA Market18.0%10% least volatile stocks in CA Market3.9%安定した株価: MOSSの株価は、 Canadian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のMOSSのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2018n/aJack Liuwww.mossgenomics.comモス・ジェノミクス社はカナダで個別化された健康、アンチエイジング、ウェルネス製品を製造・販売している。同社は以前、Nou Camp Capital Corp.として知られていたが、2021年7月にMoss Genomics Inc.に社名を変更した。モス・ジェノミクス・インクは2018年に法人化され、カナダのバンクーバーに本社を置いている。もっと見るMoss Genomics Inc. 基礎のまとめMoss Genomics の収益と売上を時価総額と比較するとどうか。MOSS 基礎統計学時価総額CA$1.90m収益（TTM）CA$0売上高(TTM)n/an/aPER（株価収益率n/aP/SレシオMOSS は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計MOSS 損益計算書（TTM）収益CA$0売上原価CA$0売上総利益CA$0その他の費用CA$0収益CA$0直近の収益報告該当なし次回決算日該当なし一株当たり利益（EPS）0グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0.0%MOSS の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 04:33終値2026/05/19 00:00収益N/A年間収益N/Aデータソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Moss Genomics Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Nov 13Moss Genomics Inc. announced that it has received CAD 0.1 million in fundingMoss Genomics Inc. announces that it has closed a non-brokered private placement of 555,555 common shares at CAD 0.18 per share for gross proceeds of CAD 100,000 on November 12, 2025. No finder’s fees were paid.
お知らせ • Aug 27Moss Genomics Inc., Annual General Meeting, Sep 29, 2025Moss Genomics Inc., Annual General Meeting, Sep 29, 2025.
New Risk • May 17New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 29% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (74% average weekly change). Market cap is less than US$10m (CA$4.62m market cap, or US$3.30m). Minor Risk Shareholders have been diluted in the past year (29% increase in shares outstanding).
お知らせ • Feb 27+ 1 more updateMoss Genomics Inc. Appoints Michal Goldstein as its Fractional Chief Financial OfficerMoss Genomics Inc. announced the appointment of Michal "Mickey" Goldstein as its new fractional Chief Financial Officer (CFO). Moss Genomics is confident that Ms. Goldstein's extensive financial expertise and leadership experience will be instrumental in supporting the Company's continued expansion and operational efficiency.
お知らせ • Feb 04Moss Genomics Inc. announced that it expects to receive CAD 0.36 million in fundingMoss Genomics Inc. announced a non-brokered private placement on February 3, 2025. The company will issue 2,000,000 common shares at price of CAD 0.18 per share for aggregate proceeds of up to CAD 360,000. The Offering may close in one or more tranches and is subject to the approval of the Canadian Securities Exchange. All securities issued under the Offering will be subject to a statutory hold period expiring four months plus one day from the date of issuance.
お知らせ • Dec 25Moss Genomics Inc. announced that it expects to receive CAD 0.25 million in fundingMoss Genomics Inc. announced a non-brokered private placement that it will issue up to 2,500,000 common shares of the company at an issue price of CAD 0.10 per share for the gross proceeds of up to CAD 250,000 on December 24, 2024. The Offering may close in one or more tranches and is subject to the approval of the Canadian Securities Exchange. All securities issued under the Offering will be subject to a statutory hold period expiring four months plus one day from the date of issuance. Additionally, the Company may pay finders' fees in connection with the Offering in accordance with the policies of the Exchange. The Company also announces that it has granted a total of 600,000 stock options to certain directors, officers and consultants of the Company. The options are each exercisable to purchase one common share of the Company at an exercise price of CAD 0.10 for a period of 5 years.
お知らせ • Nov 13Moss Genomics Inc. announced that it has received CAD 0.1 million in fundingMoss Genomics Inc. announces that it has closed a non-brokered private placement of 555,555 common shares at CAD 0.18 per share for gross proceeds of CAD 100,000 on November 12, 2025. No finder’s fees were paid.
お知らせ • Aug 27Moss Genomics Inc., Annual General Meeting, Sep 29, 2025Moss Genomics Inc., Annual General Meeting, Sep 29, 2025.
New Risk • May 17New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 29% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (74% average weekly change). Market cap is less than US$10m (CA$4.62m market cap, or US$3.30m). Minor Risk Shareholders have been diluted in the past year (29% increase in shares outstanding).
お知らせ • Feb 27+ 1 more updateMoss Genomics Inc. Appoints Michal Goldstein as its Fractional Chief Financial OfficerMoss Genomics Inc. announced the appointment of Michal "Mickey" Goldstein as its new fractional Chief Financial Officer (CFO). Moss Genomics is confident that Ms. Goldstein's extensive financial expertise and leadership experience will be instrumental in supporting the Company's continued expansion and operational efficiency.
お知らせ • Feb 04Moss Genomics Inc. announced that it expects to receive CAD 0.36 million in fundingMoss Genomics Inc. announced a non-brokered private placement on February 3, 2025. The company will issue 2,000,000 common shares at price of CAD 0.18 per share for aggregate proceeds of up to CAD 360,000. The Offering may close in one or more tranches and is subject to the approval of the Canadian Securities Exchange. All securities issued under the Offering will be subject to a statutory hold period expiring four months plus one day from the date of issuance.
お知らせ • Dec 25Moss Genomics Inc. announced that it expects to receive CAD 0.25 million in fundingMoss Genomics Inc. announced a non-brokered private placement that it will issue up to 2,500,000 common shares of the company at an issue price of CAD 0.10 per share for the gross proceeds of up to CAD 250,000 on December 24, 2024. The Offering may close in one or more tranches and is subject to the approval of the Canadian Securities Exchange. All securities issued under the Offering will be subject to a statutory hold period expiring four months plus one day from the date of issuance. Additionally, the Company may pay finders' fees in connection with the Offering in accordance with the policies of the Exchange. The Company also announces that it has granted a total of 600,000 stock options to certain directors, officers and consultants of the Company. The options are each exercisable to purchase one common share of the Company at an exercise price of CAD 0.10 for a period of 5 years.
お知らせ • May 31Moss Genomics Inc., Annual General Meeting, Jul 25, 2024Moss Genomics Inc., Annual General Meeting, Jul 25, 2024.
Board Change • May 09Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Apr 17Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Mar 18Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Nov 30Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Nov 13Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Oct 25Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 21Moss Genomics Inc. Expects to Launch Its 90-Second Urine Test and Smartphone App in December 2023Moss Genomics Inc. announced that it expects to launch its 90-second urine test and accompanying smartphone app in December 2023. This revolutionary product is set to transform the way individuals monitor their health and detect potential medical conditions, offering quick, accurate, and convenient results at their fingertips. Moss 90-second urine test utilizes cutting-edge technology to provide rapid and accurate results. By simply collecting a small urine sample, users will receive comprehensive health insights within just 90 seconds. This breakthrough technology eliminates the need for time-consuming laboratory tests. Accompanying the urine test will be a user-friendly smartphone app, providing users with a comprehensive analysis of their health data. Through the app, users will be able to track their health trends, set personalized health goals, and receive real-time notifications and recommendations based on their test results. The app will also offer a secure platform for users to share their data with healthcare professionals, enabling remote monitoring and personalized medical advice. The Moss team, alongside its partners, have worked to ensure the accuracy and reliability of the urine test and app. Extensive testing has been conducted to validate the technology's effectiveness. The results have been overwhelmingly positive, demonstrating the test's ability to detect a wide range of health conditions with high accuracy. The launch of the 90-second urine test and smartphone app is scheduled for December 2023.
Board Change • Jul 24Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jun 17Moss Genomics Inc. Introduces Diet and Vitamin ReportsMoss Genomics Inc. announced the introduction of its diet and vitamin reports which can be ordered directly to your home via its online platform. Up to 80 million genetic variants are analyzed to provide the most insightful information concerning dietary needs and vitamin deficiencies. its diet reports provide information about celiac, alcohol sensitivity, sweet tooth, caffeine related anxiety, hunger, food allergies, response to carbohydrates, bitter taste sensitivity and lactose intolerance. its Reports highlight micronutrient deficiencies and requirements such as Riboflavin, MTHFR (folate), Vitamin B12, Vitamin C, Vitamin D and Iron. These Reports give customers the opportunity to further explore and understand their genetic data. Moss customers can enjoy a comprehensive suite of genetic reports available in its online shop. Moss has created an online healthcare and technology platform integrating labs, services, and products in a shared economy. Moss provides comprehensive and affordable, at-home genetic and microbiome testing paired with personalized wellness reports and offerings to promote total gut, mind, and body health. The Company's services include health reports, personalized food and nutrition recommendations, and a social media platform that allows customers to form communities based on their specific health needs.
Board Change • Jun 01Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Mar 02Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Feb 01Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
